U.S. Markets closed

Collegium Pharmaceutical’s Oxycodone DETERx(R), an Abuse-Deterrent, Extended-Release Opioid, to be featured at PAINWeek 2013

CANTON, MA, September 3, 2013 - (ACCESSWIRE) - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that Dr. Ernest A. Kopecky, Vice President of Clinical Development and Head, Neuroscience TA at Collegium, will present a poster on Oxycodone DETERx(R) at PAINWeek 2013, taking place from September 4-7, 2013 at The Cosmopolitan in Las Vegas.

The poster, titled "Assessment of the pharmacokinetics and safety of oxycodone DETERx administered intranasally in recreational opioid users," will be displayed during the poster reception on Thursday, September 5, 2013 between 6:15 PM and 7:30 PM PDT, and will be presented orally on Friday, September 6, 2013 at 8:16 AM PDT in Condesa 4.

Additionally, Dr. Robert Taylor, Jr., Executive Director of Operations at NEMA Research, Inc., will present a poster titled "Challenges of Treating Patients with Chronic Pain with Dysphagia (CPD): Physician and Patient Perspectives," on Thursday, September 5, 2013 from 6:15 PM to 7:30 PM PDT. The poster is sponsored by Dr. Joseph Pergolizzi, Jr., Senior Partner at Naples Anesthesia and Physician Associates, Adjunct Assistant Professor at Johns Hopkins University School of Medicine, and Scientific Advisory Board member at Collegium.

About DETERx(R) Technology

The DETERx(R) drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastrostomy tube, while maintaining the extended-release properties of the product. DETERx(R) technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx(R) is the first of a number of product candidates using the DETERx(R) platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx(R) formulation platform for the treatment of chronic pain. The DETERx(R) oral drug delivery technology provides extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at http://www.collegiumpharma.com/.


Michael Heffernan, President
Collegium Pharmaceutical, Inc.

SOURCE: Collegium Pharmaceutical, Inc.